Talia Foster

Assessment of the Economic Burden of COPD in the U.S.: A Review and Synthesis of the Literature

The costs of chronic obstructive pulmonary disease (COPD) pose a major economic burden to the United States. Studies evaluating COPD costs have generated widely variable estimates; we summarized and critically compared recent estimates of the annual national and per-patient costs of COPD in the U.S. Thirteen articles reporting comprehensive estimates of the direct costs of COPD (costs related to the provision of medical goods and services) were identified from searches of relevant primary literature published since 1995. Few papers reported indirect costs of COPD (lost work and productivity). The National Heart, Lung, and Blood Institute (NHLBI) provides the single current estimate of the total (direct plus indirect) annual cost of COPD to the U.S.,

Direct costs of COPD in the U.S : An analysis of medical expenditure panel survey (MEPS) data

38.8 billion in 2005 dollars. More than half of this cost (

Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review

21.8 billion) was direct, aligning with the

The Economic Burden of Head and Neck Cancer: A Systematic Literature Review

20–26 billion range reported by two other recent analyses of large national datasets. For per-patient direct costs (in

The economic burden of metastatic breast cancer: A systematic review of literature from developed countries

US 2005), studies using recent data yield attributable cost estimates (costs deemed to be related to COPD) in the range of

Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective.

2,700–

Warfarin Exposure and the Risk of Thromboembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation

5,900 annually, and excess cost estimates (total costs incurred by COPD patients minus total costs incurred by non-COPD patients) in the range of

Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain

6,100–

Economic Burden of Follicular Non-Hodgkin’s Lymphoma

6,600 annually. Studies of both national and per-patient costs that use data approximately 8–10 years old or older have produced estimates that tend to deviate from these ranges. Cost-of-illness studies using recent data underscore the substantial current cost burden of COPD in the U.S.

PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE

Chronic obstructive pulmonary disease (COPD) is a costly cause of morbidity and mortality in the U.S. The objective of this study was to use contemporary national data—specifically, those from the 2000 Medical Expenditure Panel Survey (MEPS)—to estimate direct costs of COPD in the U.S. from an all-payer perspective. Due to constraints of MEPS data, indirect costs were excluded from our analyses, as were costs of long-term oxygen therapy and costs from nursing homes and long-term care facilities. Two methods of cost estimation were employed. First, we estimated resources used and expenditures incurred by individuals with COPD that were directly attributable to the disease (attributable cost approach). Second, we compared overall medical expenditures of patients with COPD to those of the non-COPD population; the resulting difference represented excess costs of COPD. Approximately 1.7% (n = 144) of the nearly 8,300 persons in the analysis data set aged ≥ 45 years used medical resources and incurred expenditures related to treatment of COPD. Mean attributable costs per patient were estimated at